Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.
Hosted on MSN20h
Celltrion gets U.S. FDA approval for new biosimilar for autoimmune disease treatmentCelltrion Inc., a major South Korean biopharmaceutical firm, said Friday its new biosimilar for an autoimmune disease treatment has received approval from the U.S. Food and Drug Administration (FDA).
The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both ...
Korea Joongang Daily on MSN16h
Celltrion's Actemra biosimilar gets FDA approvalCelltrion's biosimilar Avtozma, used to treat inflammatory diseases, was approved for the U.S. market by the Food and Drug Administration.
As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...
The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.
US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...
On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...
The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.
An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...
The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an ...
JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback